Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$102.96 USD

102.96
5,272,970

+0.01 (0.01%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $102.92 -0.04 (-0.04%) 7:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Is This the Right Time to Hold ALGN Stock in Your Portfolio?

by Zacks Equity Research

Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.

Zacks Equity Research

ABT Stock Gains Following the Positive TRILUMINATE Trial Results

by Zacks Equity Research

Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.

Zacks Equity Research

Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now

by Zacks Equity Research

Merit Medical's strong product portfolio raises optimism about the stock.

Zacks Equity Research

Boston Scientific (BSX) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

Boston Scientific (BSX) reachead $100.88 at the closing of the latest trading day, reflecting a +1.53% change compared to its last close.

Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain OPKO Health Stock in Your Portfolio

by Zacks Equity Research

OPK's growth is fueled by Rayaldee's success and promising pipeline progress. However, margin pressure and overdependence on its lead product are concerning.

Zacks Equity Research

Thermo Fisher's New Deal With CZ Imaging Institute May Boost Its Stock

by Zacks Equity Research

TMO and CZ Imaging Institute to collaborate on further understanding of human cells.

Zacks Equity Research

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

by Zacks Equity Research

ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.

Zacks Equity Research

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?

by Zacks Equity Research

Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.

Zacks Equity Research

International Expansion, Product Launches Support BSX Stock

by Zacks Equity Research

Boston Scientific continues to successfully expand its operations across various geographies outside the United States.

Zacks Equity Research

Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win

by Zacks Equity Research

INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.

Zacks Equity Research

Here's Why You Should Hold AVTR Stock in Your Portfolio for Now

by Zacks Equity Research

Avantor is set for growth with a strong portfolio and solid fourth quarter results, but challenges like customer losses and forex volatility pose potential risks.

Zacks Equity Research

Should You Retain Exact Sciences Stock in Your Portfolio Now?

by Zacks Equity Research

EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.

Zacks Equity Research

CAH Stock Rises More Than 13% YTD: Should You Buy, Hold or Sell?

by Zacks Equity Research

Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.

Zacks Equity Research

DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval

by Zacks Equity Research

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.

Zacks Equity Research

Is Quest Diagnostics Stock Worth Holding Onto Right Now?

by Zacks Equity Research

Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.

Zacks Equity Research

National Vision Stock Rises 28.2% YTD: Will the Rally Continue?

by Zacks Equity Research

EYE's strength in its largest brand and actions to achieve a healthier store fleet position the stock favorably.

Zacks Equity Research

The Zacks Analyst Blog Highlights Tesla, The Home Depot, Boston Scientific, Frequency Electronics and Bridger Aerospace

by Zacks Equity Research

Tesla, The Home Depot, Boston Scientific, Frequency Electronics and Bridger Aerospace are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Tesla, Home Depot & Boston Scientific

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, Inc. (HD) and Boston Scientific Corp. (BSX), as well as two micro-cap stocks Frequency Electronics, Inc. (FEIM) and Bridger Aerospace Group Holdings, Inc. (BAER).

Zacks Equity Research

Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results

by Zacks Equity Research

MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.

Zacks Equity Research

Allurion Technologies, Inc. (ALUR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of -40% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is This the Right Time to Hold Integra Stock in Your Portfolio?

by Zacks Equity Research

IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.

Zacks Equity Research

DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor

by Zacks Equity Research

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.

Zacks Equity Research

BDX Stock Declines Following Class I Classification for Alaris Recall

by Zacks Equity Research

BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.

Urmimala Biswas headshot

Does the S&P 500 Rally Make MDT Stock a Buy Amid Easing Trade Tension?

by Urmimala Biswas

Medtronic's Hypertension business is on the brink of a major expansion, driven by its Simplicity blood pressure procedure.